Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2164929 | 0.83 | ALOX5 (0.58) | MAOBNR4A1NR4A2NR4A3ALOX5 | |
| SCHEMBL7908556 | 0.81 | MAOB (0.56) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL1923823 | 0.80 | LMNA (0.52) | PPARALMNA | |
| SCHEMBL7167438 | 0.80 | MAOB (0.58) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL7864559 | 0.80 | FFAR1 (0.48) | MAOBNR4A1NR4A2NR4A3ALOX5 | |
| SCHEMBL2241050 | 0.79 | AKR1C3 (0.51) | L3MBTL1FFAR1 | |
| SCHEMBL11490483 | 0.79 | NR4A1 (0.60) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL2848849 | 0.79 | NR4A1 (0.60) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL5722245 | 0.79 | NR4A1 (0.60) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL6190389 | 0.79 | LMNA (0.58) | MAOBNR4A1NR4A2NR4A3ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223881-B2 | Process for the preparation of new antidiabetic agents | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-05-29 | — | — | US | disclosed |
| US-20030125553-A1 | Process for the preparation of new antidiabetic agents | DR. REDDY'S LABORATORIES LIMITED | 2003-07-03 | — | — | US | disclosed |
| US-6531596-B1 | S(-)-2-methoxy-3-(4-(2-(phenoxazin-10-yl)methoxy) phenyl)propionic acid; benzylating p-hydroxybenzaldehyde or tyrosine; reaction with phenoxazinyl mesylate | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-03-11 | — | — | US | disclosed |
| EP-1124808-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125553-A1 | Process for the preparation of new antidiabetic agents | GLP1R, GPR119, SLC5A1 | MAOB 2027/4885NR4A1 488/4885NR4A2 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.